Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor

Trial Profile

Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Abdominal aortic aneurysm; Acute coronary syndromes; Angina pectoris; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 30 Apr 2022 Results (n=175) assessing effect of genetic polymorphism Including NUP153 and SVEP1 on the pharmacokinetics and pharmacodynamics of Ticagrelor of healthy Chinese subjects published in the Clinical Drug Investigation
    • 19 Dec 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
    • 19 Dec 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top